Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioLife Solutions, Inc. before investing.

In this article, we go over a few key elements for understanding BioLife Solutions, Inc.’s stock price such as:

• BioLife Solutions, Inc.’s current stock price and volume
• Why BioLife Solutions, Inc.’s stock price changed recently
• Upgrades and downgrades for BLFS from analysts
• BLFS’s stock price momentum as measured by its relative strength

About BioLife Solutions, Inc. (BLFS)

Before we jump into BioLife Solutions, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Want to learn more about BioLife Solutions, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioLife Solutions, Inc..

BioLife Solutions, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BioLife Solutions, Inc.’s stock price was $31.280.

BioLife Solutions, Inc. is down 1.14% from its previous closing price of $31.640.

During the last market session, BioLife Solutions, Inc.’s stock traded between $31.020 and $31.700. Currently, there are approximately 48.46 million shares outstanding for BioLife Solutions, Inc..

BioLife Solutions, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BioLife Solutions, Inc. Stock Price History

BioLife Solutions, Inc.’s (BLFS) price is currently up 10.76% so far this month.

During the month of July, BioLife Solutions, Inc.’s stock price has reached a high of $33.140 and a low of $26.983.

Over the last year, BioLife Solutions, Inc. has hit prices as high as $33.140 and as low as $17.860. Year to date, BioLife Solutions, Inc.’s stock is up 29.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BioLife Solutions, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 31, 2026,, no analysts have changed their rating of BioLife Solutions, Inc.’s stock over the last month.

Additionally, you'll want to evaluate BioLife Solutions, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioLife Solutions, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BioLife Solutions, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioLife Solutions, Inc. (BLFS) by visiting AAII Stock Evaluator.

Relative Price Strength of BioLife Solutions, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, BioLife Solutions, Inc. has a weighted four-quarter relative price strength of 15.15%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how BioLife Solutions, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioLife Solutions, Inc. Stock Price: Bottom Line

As of July 31, 2026, BioLife Solutions, Inc.’s stock price is $31.280, which is down 1.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioLife Solutions, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.